Condition: Chronic Kidney Disease · Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial designed to investigate the efficacy and safety of different doses of sal0120 tablets in patients with CKD.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07716618